Pulmonary hypertension can be caused by a variety of other conditions, often making it difficult to distinguish. A problem that medical professionals often encounter is differentiating pulmonary arterial hypertension (PAH)…
According to Medical Xpress, a new gene therapy has been studied for the treatment of Duchenne muscular dystrophy. This treatment, SRP-9001, has been shown to deliver micro-dystrophin and improve functional…
Ultragenyx Pharmaceutical's therapy, CRYSVITA, has recently been approved by the FDA for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors. This approval comes after…
Aridis Pharmaceuticals has released the data from the first phase of its clinical trial of AR-501. This treatment is inhaled to clear lung infections that are commonly experienced by those…
Cures Within Reach is an organization that aims to help patients by repurposing research. They work towards getting treatments quickly and safely in an effort to aid those who need…
According to Myasthenia Gravis News, CAAR T-cell therapy may be a viable treatment option for those with myasthenia gravis. Researchers from the University of Pennsylvania, Yale Medical School, and Cabaletta…
According to the ASCO Post, researchers have discovered genomic characteristics of smoldering multiple myeloma that can tell one's risk of progression to multiple myeloma. Dr. Mark Bustoros and his team…
.jpg)
Summer is approaching, and Lyme disease is coming with it. Ticks and wildlife are more active in the warmer months, leading to an increase in tick-spread diseases. But because we…
According to Healio, US veterans affected by pulmonary arterial hypertension are typically not treated with exercise rehabilitation, despite the fact that many medical professionals believe that utilizing exercise rehabilitation in…
Acadia Pharmaceuticals recently released the results of their Phase 3 trial of Nuplazid, a treatment for the psychosis that Parkinson's disease patients experience. This medication has been approved since 2016,…
Gut bacteria has been connected to a number of conditions: depression, diabetes, and now Parkinson's disease. A study published in Annals of Neurology has shown that gut bacteria is linked…
A recent study that utilized the COVID-19 Global Rheumatology Alliance registry has evaluated the risks that the novel coronavirus brings to those with lupus and other rheumatic diseases, as reported…
PharmaEssentia Corporation, a biopharmaceutical company located in Burlington, Massachusetts, has recently seen their Biologics License Application (BLA) approved by the FDA. This application was submitted for ropeginterferon alfa-2b, a treatment…
Se realizó un estudio que podría ser el rituximab puede ser preferible a los tratamientos tradicionales para la miastenia gravis. También concluyó que el tiuximab es el más efectivo si…
Ultomiris, a product of Alexion Pharmaceuticals, has recently been studied in a Phase 3 clinical trial. This study was intended to ultomiris' effect on life-threatening complications of atypical hemolytic uremic…
Many myasthenia gravis patients do not benefit from already existing therapies, such as steroids, acetylcholinesterase inhibitors, or immunosuppressants. It is this fact that has pushed many biotechnology companies to start…
Immune-Onc Therapeutics recently received clearance from the FDA to begin trials of IO-202, a treatment for acute myeloid leukemia (AML). This news comes after the cancer immunotherapy company filed an…
The European Commission has recently granted approval to Bristol Myers Squibb (BMS) for their multiple sclerosis (MS) treatment, Zeposia. It has already been approved by the FDA in the US…
Medical professionals are already aware that inhaling air pollution can increase one's risk of a number of conditions, including respiratory and heart diseases. They are now discovering that it can…
Libtayo, a product of Regeneron Pharmaceuticals, has shown positive results in the treatment of those with advanced cutaneous squamous cell carcinoma. This data comes from a Phase 2 trial and…
.jpg)
Neurotrope is launching a long term Phase 2 trial of Bryostatin-1, which is a treatment for Alzheimer's disease. The National Institutes of Health (NIH) will be joining this study, giving…
Parent Project Muscular Dystrophy is a nonprofit that aims to find a cure for Duchenne muscular dystrophy. One of their programs, the Certified Duchenne Care Center Program (CDCCP), has recently…
CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…
Anavex Life Sciences Corporation has recently announced that they will conduct a clinical trial for their small molecule, ANAVEX®3-71. This therapy is intended to treat neurodegenerative and neurodevelopmental conditions, such…
Passage Bio has been granted the Rare Pediatric Disease designation for their GM1 gangliosidosis treatment, PBGM01. This designation means that Passage will receive a priority review voucher, and it is…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
